Ahlskog JE - Search Results

1

Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.

Chung SJ, Armasu SM, Anderson KJ, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, Ahlskog JE, Frigerio R, Maraganore DM. Chung SJ, et al. Among authors: ahlskog je. Parkinsonism Relat Disord. 2013 Jun;19(6):595-9. doi: 10.1016/j.parkreldis.2013.02.008. Epub 2013 Mar 16. Parkinsonism Relat Disord. 2013. PMID: 23507417 Free PMC article.

2

Movement disorders as sequelae of central pontine myelinolysis: report of three cases.

Maraganore DM, Folger WN, Swanson JW, Ahlskog JE. Maraganore DM, et al. Among authors: ahlskog je. Mov Disord. 1992;7(2):142-8. doi: 10.1002/mds.870070208. Mov Disord. 1992. PMID: 1584236 Review.

3

Guamanian neurodegenerative disease: investigation of the calcium metabolism/heavy metal hypothesis.

Ahlskog JE, Waring SC, Kurland LT, Petersen RC, Moyer TP, Harmsen WS, Maraganore DM, O'Brien PC, Esteban-Santillan C, Bush V. Ahlskog JE, et al. Neurology. 1995 Jul;45(7):1340-4. doi: 10.1212/wnl.45.7.1340. Neurology. 1995. PMID: 7617195

4

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Collins SJ, et al. Among authors: ahlskog je. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):167-73. doi: 10.1136/jnnp.58.2.167. J Neurol Neurosurg Psychiatry. 1995. PMID: 7876846 Free PMC article.

5

Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K. Ahlskog JE, et al. Arch Neurol. 1994 Dec;51(12):1236-41. doi: 10.1001/archneur.1994.00540240080020. Arch Neurol. 1994. PMID: 7986180 Clinical Trial.

6

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.

Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC. Uitti RJ, et al. Among authors: ahlskog je. Neurology. 1993 Oct;43(10):1918-26. doi: 10.1212/wnl.43.10.1918. Neurology. 1993. PMID: 8413948

7

Does levodopa therapy delay death in Parkinson's disease?

Uitti RJ, Ahlskog JE, Maraganore DM. Uitti RJ, et al. Among authors: ahlskog je. Mov Disord. 1996 May;11(3):343-4. Mov Disord. 1996. PMID: 8723162 No abstract available.

8

Intranasal apomorphine rescue therapy for parkinsonian "off" periods.

Dewey RB Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. Dewey RB Jr, et al. Among authors: ahlskog je. Clin Neuropharmacol. 1996 Jun;19(3):193-201. doi: 10.1097/00002826-199619030-00001. Clin Neuropharmacol. 1996. PMID: 8726538 Clinical Trial.

9

Treatment of putative immune-mediated and idiopathic cervical dystonia with intravenous methylprednisolone.

Kumar R, Maraganore DM, Ahlskog JE, Rodriguez M. Kumar R, et al. Among authors: ahlskog je. Neurology. 1997 Mar;48(3):732-5. doi: 10.1212/wnl.48.3.732. Neurology. 1997. PMID: 9065556

10

Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota.

Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Chabolla DR, et al. Among authors: ahlskog je. Mayo Clin Proc. 1998 Aug;73(8):724-7. doi: 10.4065/73.8.724. Mayo Clin Proc. 1998. PMID: 9703296

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

292 results

Search Page